For initiation and early progression of primary prostate cancer, several driver mutations or alterations have been described e.g., inactivating SPOP mutations, activating FOXA1 mutations, TMPRRS-ERG fusion, loss of PTEN or AR alterations. This evidence concerns the gene AR and prostate carcinoma.